ArticleInternational journal of nanomedicine2022
Development and in vivo Evaluation of Hydroxy-α-Sanshool Intranasal Liposomes as a Potential Remedial Treatment for Alzheimer's Disease.
Article in International journal of nanomedicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 30 citations in OpenAlex.
- Advances in Nose-to-Brain Delivery Systems for Effective Alzheimer's Disease Management.Current Alzheimer research · 2026Review
- Liposomal and Nanomaterial-Based Strategies for Targeted Alzheimer's Disease Therapy.ACS omega · 2025Review
- Luliconazole-Loaded Nanoliposomes as a Repurposing Strategy to Combat Memory Dysfunction in LPS-Induced Alzheimer's Rats.ACS omega · 2025Article
- The Nasal-Brain Drug Delivery Route: Mechanisms and Applications to Central Nervous System Diseases.MedComm · 2025Review
- Advancements in Nanocarrier Systems for Nose-to-Brain Drug Delivery.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Evolution of Alzheimer's Disease Therapeutics: From Conventional Drugs to Medicinal Plants, Immunotherapy, Microbiotherapy and Nanotherapy.Pharmaceutics · 2025Review
- Nose-to-brain Drug Delivery System: An Emerging Approach to Chemotherapy-induced Cognitive Impairment.Pharmaceutical nanotechnology · 2025Review
- Non-pharmacological treatment of Alzheimer's disease: an update.Frontiers in aging neuroscience · 2025Review
- Review
- Sodium Alginate/Chitosan-Coated Liposomes for Oral Delivery of Hydroxy-α-Sanshool: In Vitro and In Vivo Evaluation.Pharmaceutics · 2023Article
- Recent Advances in Intranasal Liposomes for Drug, Gene, and Vaccine Delivery.Pharmaceutics · 2023Review
- Regulation of mitochondrial dysfunction induced cell apoptosis is a potential therapeutic strategy for herbal medicine to treat neurodegenerative diseases.Frontiers in pharmacology · 2022Review
- Nanomedicines in the Management of Alzheimer's Disease: Current View and Future Prospects.Frontiers in aging neuroscience · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeHydroxy-α-sanshool (HAS) improves cognitive dysfunction, but its structural instability has limited its clinical application. The present study was conducted to investigate the optimal formulation of hydroxy-α-sanshool liposomes (HAS-LPs) and its effect on ameliorating learning and memory disorders in an Alzheimer's disease (AD) model.
methodsIn this study, HAS was prepared as HAS-LP using a thin film dispersion method. After selecting the optimal preparation conditions, HAS-LP was characterized using transmission electron microscopy (TEM) and by measuring the zeta potential, particle size, and in vitro drug release. Next, evaluated the effect of HAS-LP on the rat nasal mucosa and then applied it to AD mice. By performing behaviour experiments, pathological test and related pharmacokinetic parameters, we explored its effect on attenuating learning and memory impairment in mice.
resultsWhen the mass ratio of HAS:cholesterol:soybean lecithin was 1:4:16 and 15 mL of ultrapure water were added, the highest encapsulation efficiency and drug loading were obtained. HAS-LP had a particle size of 181.77 nm, a polydispersity index of 0.207 and a zeta potential of -53.8 mV, and it remained stable at 25 °C for 1 week and 4 °C for 8 weeks. Moreover, HAS-LP exhibited slow drug release and was highly consistent with the Higuchi release model. HAS-LP was not significantly toxic to the nasal mucosa and effectively alleviated D-galactose-induced learning memory deficits and protected mouse hippocampal neuronal cells. HAS-LP was highly enriched in plasma and brain tissue after administration via the nasal route and obtained some ability to target the brain.
conclusionHAS encapsulated in soybean lecithin and cholesterol was successfully developed, suggesting that treatment with the nanoparticles might reverse some AD symptoms. Therefore, these nanoparticles might be used as promising new candidates for the delivery of HAS to treat AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.